In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir | Zendy

Bin Han | Zendy; Bandita Parhy | Zendy; Julia Lu | Zendy; Eric S. Zhou | Zendy; David Hsieh | Zendy; Grégory Camus | Zendy; Ross Martin | Zendy; Evguenia S. Svarovskaia | Zendy; Hongmei Mo | Zendy; Hadas DvorySobol | Zendy

Open Access

In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir

Author(s) -

Bin Han,

Bandita Parhy,

Julia Lu,

Eric S. Zhou,

David Hsieh,

Grégory Camus,

Ross Martin,

Evguenia S. Svarovskaia,

Hongmei Mo,

Hadas DvorySobol

Publication year - 2019

Publication title -

journal of clinical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.349

H-Index - 255

eISSN - 1070-633X

pISSN - 0095-1137

DOI - 10.1128/jcm.01844-18

Subject(s) - virology , genotype , ns3 , hepatitis c virus , in vitro , biology , flaviviridae , hepacivirus , virus , microbiology and biotechnology , medicine , genetics , gene

Voxilaprevir is a direct-acting antiviral agent (DAA) that targets the NS3/4A protease of hepatitis C virus (HCV). High sequence diversity of HCV and inadequate drug exposure during unsuccessful treatment may lead to the accumulation of variants with reduced susceptibility to DAAs, including NS3/4A protease inhibitors such as voxilaprevir.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research